Tenvie
tenvie.com
Immunology & Inflammation Therapeutics
Neurology & CNS Therapeutics
As featured in
Claim pageClaim
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
11-50
employees, estimated range
Backers
3
ARCH Venture Partners, Eight Roads
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
ARCH Venture Partners 
Eight Roads Overview
Tenvie is a biopharmaceutical company developing precision-engineered small molecule therapies for neurological and peripheral diseases driven by neuroinflammation and cellular dysfunction. Its product engine can advance both fully CNS-penetrant and peripherally restricted products, and it recruits clinical development scientists. The company is headquartered in Brisbane, Australia.
News
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV108, an Allosteric SARM1 inhibitor
Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV108, an Allosteric SARM1 inhibitor
Read more
Report
Tenvie Therapeutics Appoints Don O'Sullivan, Ph.D., MBA, as Chief Business Officer
Seasoned biotechnology executive with more than 20 years of corporate and business development experience to lead strategic collaborations and business operations
Read more
Report
Tenvie Therapeutics Promotes Tony Estrada, PhD, to Chief Executive Officer
Proven drug development leader to drive company's pipeline of highlyCNS-penetrant and precision-designed peripherally restricted small molecules toward clinical milestones
Read more
Report
Tenvie Therapeutics Promotes Tony Estrada, PhD, to Chief Executive Officer
Proven drug development leader to drive company's pipeline of highly CNS-penetrant and precision-designed peripherally restricted small molecules toward clinical milestonesSOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Tenvie Therapeutics,
Read more
Report
Tenvie Therapeutics Raises $200 Million For Delivering Small Molecule Therapies
Tenvie Therapeutics announced that it recently launched with a commitment to transform the treatment of neurological diseases. And the company raised $200 million in funding led by ARCH Venture Partners, F-Prime Capital, Mubadala Capital, with participati
Read more
Report
Denali Therapeutics spinout raises $200M as neuro company resets
Tenvie is carrying over a collection of small molecule drugs that Denali had been developing but decided to discontinue work on.
Read more
Report
Tenvie Therapeutics Launches with $200 Million to Deliver Breakthrough Small Molecule Therapies
Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases Led by expert R&D leadership team with proven ability to develop therapies for CNS and peripheral diseases ARCH Venture Partners, F-Prime
Read more
Report
Tech stack
Technologies named in job postings at Tenvie over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
64/100
Cloud & platforms
GCP
Sign in to see how your skills match this stack
Sign In
Growth
Hiring Momentum
28/100
Slowing
Open positions
0
0 opened / 0 closed in 30 days
Median time-to-fill
20 days
faster than 56% of the market
ATS activity
Every ~12 hours
10/27/2026
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
100% ▲
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Brisbane
Australia
HQ
1 posted in 90 days 10-50 est. staff